University of British Columbia-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:University of British Columbia - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013631
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
University of British Columbia (UBC) is a research institute that offers educational services. The university provides undergraduate, graduate educational programs, and research programs through its schools and faculties. It provides cultural, recreational and social activities for its students. UBC offers educational services through programs such a professional programs, English language pathways, joint academic programs, exchange programs, co-operative education, innovative learning initiatives and distance education programs. The university serves adult education needs of lifelong learners by providing educational programs in UBC’s Point Grey campus. It operates through peer institutions, government, non-profit and other industries for its research activities. The university operates in two campuses namely, Vancouver Campus and Okanagan Campus. UBC is headquartered in Vancouver, British Columbia, Canada

University of British Columbia – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
University of British Columbia, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
University of British Columbia, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
University of British Columbia, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
University of British Columbia, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
University of British Columbia, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
University of British Columbia, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
AXIM Biotech Enters into Agreement with University of British Columbia 12
Replicel Life Sciences Enters into Agreement with University of British Columbia 13
Ritter Pharma Enters into Agreement with University of British Columbia 14
TxCell Enters into Research Agreement with University of British Columbia 15
ProtoKinetix Enters into Research Agreement with University of British Columbia 16
Sirona Biochem Enters into Research Agreement with University of British Columbia 17
Qu Biologics Enters into Research Agreement with University of British Columbia 18
InMed Pharma Enters into Agreement with University of British Columbia 19
University of British Columbia Enters Into Agreement With Sichuan BoXin LaiTe Biotechnology And Heracles International Investment 20
Cangene Enters Into Research Agreement With University Of British Columbia 21
AlCana Extends Co-Development Agreement With UBC And Alnylam 22
CDRD Enters Into Co-Development Agreement With NGDI-UBC 23
Licensing Agreements 24
Roche Enters into Licensing Agreement with University of British Columbia and Vancouver Coastal Health Research Institute 24
BirchBioMed Enters into Licensing Agreement with University of British Columbia 25
Cyon Therapeutics Enters into Licensing Agreement with University of British Columbia 26
Cangene Enters Into Licensing Agreement With University of British Columbia 27
Advanced Inhalation Therapies Enters into Licensing Agreement with University of British Columbia 28
University of British Columbia – Key Competitors 29
University of British Columbia – Key Employees 30
University of British Columbia – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 33
Government and Public Interest 33
Oct 03, 2017: Avon Foundation for Women (Canada) funds new breast cancer recovery trial in partnership with two Canadian universities 33
Sep 12, 2017: Alzheimer Society Research Program provides $3.4 million boost to dementia research 34
Jul 28, 2017: UBC researchers working to engineer ‘tunable’ insulin production 35
Nov 16, 2016: Marijuana could Help Treat Drug Addiction, Mental Health 36
Jul 15, 2016: Cell research could help with heart tissue transplants 37
Jun 16, 2016: BC Children’s Hospital researchers discover an early warning sign of transplant rejection 38
Jun 01, 2016: UBC-Vancouver Coastal Health scientists find genetic cause of multiple sclerosis 39
May 02, 2016: Childhood asthma research receives $2 million to investigate genetic and environmental factors 41
Apr 06, 2016: Results of World’s First Study on New Treatment for Heroin Addiction 42
Product News 43
Oct 26, 2017: Vanderbilt leads international effort to develop universal flu vaccine 43
Sep 28, 2016: Antibiotics developed in 1960s show promise for TB therapy 44
Sep 07, 2016: UBC and Tilray Launch Canada’s First Clinical Trial to Study Medical Cannabis and PTSD 45
Clinical Trials 46
Oct 13, 2016: OncoGenex Announces Results from the Phase 3 ENSPIRIT Trial of Custirsen in Non-Small Cell Lung Cancer 46
Oct 10, 2016: ESMO 2016: Custirsen Shows no Survival Benefits in Metastatic Prostate Cancer 47
Aug 16, 2016: OncoGenex Announced Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer 48
Other Significant Developments 49
Oct 26, 2017: The Human Vaccines Project Launches New Initiative To Accelerate Development Of Universally Effective Influenza Vaccines 49
Oct 17, 2017: Scientific Update for Diabetes, Kidney Ischemia, Liver Perfusion, Retinal Cell Replacement, Monoclonal Antibody Production and Immune Cell Cryopreservation Recovery 50
Jun 24, 2016: Genome British Columbia Investing in Companies and Jobs Through e@UBC 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
University of British Columbia, Pharmaceuticals & Healthcare, Key Facts 2
University of British Columbia, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
University of British Columbia, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
University of British Columbia, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
University of British Columbia, Deals By Therapy Area, 2011 to YTD 2017 9
University of British Columbia, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
AXIM Biotech Enters into Agreement with University of British Columbia 12
Replicel Life Sciences Enters into Agreement with University of British Columbia 13
Ritter Pharma Enters into Agreement with University of British Columbia 14
TxCell Enters into Research Agreement with University of British Columbia 15
ProtoKinetix Enters into Research Agreement with University of British Columbia 16
Sirona Biochem Enters into Research Agreement with University of British Columbia 17
Qu Biologics Enters into Research Agreement with University of British Columbia 18
InMed Pharma Enters into Agreement with University of British Columbia 19
University of British Columbia Enters Into Agreement With Sichuan BoXin LaiTe Biotechnology And Heracles International Investment 20
Cangene Enters Into Research Agreement With University Of British Columbia 21
AlCana Extends Co-Development Agreement With UBC And Alnylam 22
CDRD Enters Into Co-Development Agreement With NGDI-UBC 23
Roche Enters into Licensing Agreement with University of British Columbia and Vancouver Coastal Health Research Institute 24
BirchBioMed Enters into Licensing Agreement with University of British Columbia 25
Cyon Therapeutics Enters into Licensing Agreement with University of British Columbia 26
Cangene Enters Into Licensing Agreement With University of British Columbia 27
Advanced Inhalation Therapies Enters into Licensing Agreement with University of British Columbia 28
University of British Columbia, Key Competitors 29
University of British Columbia, Key Employees 30
University of British Columbia, Other Locations 31
University of British Columbia, Subsidiaries 31

★海外企業調査レポート[University of British Columbia-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Harsoria Healthcare Pvt Ltd:企業の戦略的SWOT分析
    Harsoria Healthcare Pvt Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Morgan Advanced Materials plc (MGAM):企業の財務・戦略的SWOT分析
    Summary Morgan Advanced Materials Plc (Morgan) is a diversified company. The company designs, manufactures and markets technical ceramics, thermal ceramics, molten metal systems, electrical carbon, braze alloys, fire protection products, seals and bearings, specialty graphite, and composites and def …
  • Johnson Service Group plc (JSG):企業の財務・戦略的SWOT分析
    Summary Johnson Service Group plc (JSG) is a business and consumer service provider that provides textile services. The company provides dry cleaning and textile rental services. It offers dry cleaning services such as commercial dry cleaning, specialist textile consulting, garment aftercare service …
  • Repsol SA (REP):電力:M&Aディール及び事業提携情報
    Summary Repsol SA (Repsol) is an integrated oil and gas company. It has presence across the entire value chain: exploration and production, transformation, development and marketing of energy. The company’s upstream business carries out oil and natural gas exploration and production. Its downstream …
  • TAS Energy Inc:企業の戦略的SWOT分析
    TAS Energy Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Natra S.A.:企業の戦略・SWOT・財務分析
    Natra S.A. - Strategy, SWOT and Corporate Finance Report Summary Natra S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • The Navigator Company:企業の戦略・SWOT・財務情報
    The Navigator Company - Strategy, SWOT and Corporate Finance Report Summary The Navigator Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Callitas Therapeutics Inc (LILY):医療機器:M&Aディール及び事業提携情報
    Summary Callitas Therapeutics Inc (Callitas Therapeutics), formerly M Pharmaceutical Inc, is a drug discovery and development company that offers ground-breaking drug treatments and biomedical technologies. The company’s products include weight management products, infertility products and women’s h …
  • AF Gruppen ASA (AFG):企業の財務・戦略的SWOT分析
    AF Gruppen ASA (AFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Telkom SA SOC Limited (TKG):企業の財務・戦略的SWOT分析
    Telkom SA SOC Limited (TKG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Pacific Edge Ltd (PEB):製品パイプライン分析
    Summary Pacific Edge Ltd (PEB) is a diagnostics company that discovers, develops and commercializes diagnostic tests for the early detection and monitoring of cancer. The company provides lead product such as Cxbladder, a non-invasive laboratory test for the detection of bladder cancer. It is develo …
  • BioView Ltd (BIOV):企業の財務・戦略的SWOT分析
    BioView Ltd (BIOV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Balaji Amines Ltd (BALAMINES)
    Balaji Amines Ltd (BALAMINES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Cytori Therapeutics Inc (CYTX):医療機器:M&Aディール及び事業提携情報
    Summary Cytori Therapeutics Inc (Cytori) is a clinical stage cell therapy company. It develops cell therapies from autologous adipose-derived regenerative cells (ADRCs) for the treatment of cardiovascular disease, orthopedic conditions and gastrointestinal disorders. The company has two therapeutic …
  • TRACON Pharmaceuticals Inc (TCON):製薬・医療:M&Aディール及び事業提携情報
    Summary TRACON Pharmaceuticals Inc (TRACON) is a biopharmaceutical company that develops and commercializes targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. The company offers pipeline products such as TRC105, TRC102, TRC253, TRC694, and TRC205. Its lead product …
  • Wellcome Trust Sanger Institute-製薬・医療分野:企業M&A・提携分析
    Summary Wellcome Trust Sanger Institute (Sanger Institute), a subsidiary of Genome Research Ltd is a genomic discovery and research centre that carries out research and development in the areas of cellular and human genetics and infection genomics. It also provides postgraduate training on research …
  • Barry Callebaut AG:企業のM&A・事業提携・投資動向
    Barry Callebaut AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Barry Callebaut AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Lee’s Pharmaceutical Holdings Ltd (950):製薬・医療:M&Aディール及び事業提携情報
    Summary Lee's Pharmaceutical Holdings Ltd (Lee's Pharmaceutical) is a biopharmaceutical company that offers development of novel therapies and contract research services. The company provides products in the treatment of disease areas such as urology, cardiovascular oncology, dermatology, hematology …
  • Shui On Land Limited:企業の戦略・SWOT・財務情報
    Shui On Land Limited - Strategy, SWOT and Corporate Finance Report Summary Shui On Land Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Enterprise Rent-A-Car Company:企業の戦略・SWOT・財務分析
    Enterprise Rent-A-Car Company - Strategy, SWOT and Corporate Finance Report Summary Enterprise Rent-A-Car Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆